ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS

CtDNA detection as a noninvasive detection method, can truly reflect the real tumor tissue gene mutation map and frequency, is the evaluation of therapeutic effect and the important monitoring indicators of clinical follow-up after treatment. The second generation of high-throughput gene sequencing (NGS) is an important means of detecting ctDNA, which can detect trace ctDNA from smaller plasma samples. The ctDNA dynamic monitoring of stage I non-small cell lung cancer (NSCLC) was performed by the second generation gene sequencing (NGS) technique to verify the prognostic predictive effect of ctDNA in stage I NSCLC patients without radiotherapy and targeted therapy.

Inclusion criteria

• Postoperative histopathological diagnosis of TNM stage IA / IB NSCLC with R0 resection;
• No adjuvant chemotherapy, radiotherapy, targeted drug therapy or biotherapy after surgery;

General selection criteria:

• Men or women of age ≥18 years and <75 years old;
• ECOG behavior status score 0 to 1;

Exclusion criteria

• Patients with other cancers other than NSCLC within five years prior to this study;
• who can not get enough tumor histological specimens (non-cytological) for analysis;
• human immunodeficiency virus (HIV) infection;
• NSCLC mixed with patients with small cell lung cancer;
• pregnant or lactating women;
• There is a clear history of neurological or mental disorders, including epilepsy or dementia;
• Conditions that investigators think is not suitable for inclusion.